Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

AIDS

Volumn 12, Issue 18, 1998, Pages 2433-2437

  Brodie, Sharon B ^a,b   Keller, Maria J ^a   Ewenstein, Bruce M ^a   Sax, Paul E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Hemophilia; Hepatitis C virus; HIV; Indinavir; Nephrolithiasis

Indexed keywords

INDINAVIR;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032564583     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199818000-00012     Document Type: Article

References (31)

1. Hammer SM, Squires KE, Hughes MD: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
3. Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L: Saquinavir (Invirase) vs. Hivid (zalcitabine) vs. combination as treatment for advanced HIV infection in patients discontinuing unable to take Retrovir (zidovudine). XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.410].
4. Carpenter CCJ, Fischl MA, Hammer SM: Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society - USA panel. JAMA 1997, 277:1962-1969.
5. Merck & Co. Inc.: Crixivan (indinavir sulfate) product monograph. West Point, Passadena 1997.
6. Merck & Co. Inc.: Crixivan (indinavir sulfate) product monograph. West Point, Passadena, 1996.
7. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
8. Flexner C: HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
9. Kopp JB, Miller KD, Mican JAM, et al.: Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997, 127:119-125.
10. Mauss S, Niepmann H, Medwe M, Haussinger D, Jablonowski H: Increased incidence of nephrolithiasis and flank pain in HIV seropositive individuals treated with indinavir. 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-184].
11. Polyak B, Henley DB, Maudlin J, Postelnick M, Hirschtick R: The clinical incidence of nephrolithiasis in HIV-positive patients receiving indinavir. 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto. Ontario, September 1997 [abstract 1-183].
12. John H, Muller NJ, Opravil M, Hauri D: Indinavir urinary stones as origin of upper urinary tract obstruction, Urology Int 1997, 59:257-259.
13. Makris M, Preston FE: Chronic hepatitis in haemophilia. Blood Rev 1993, 7:243-250.
14. van den Hoek JAR, van Haastrecht HJA, Goudsmit J, de Wold F, Coutinho KA: Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990, 162:823-826.
15. Thomas DL, Shih JW, Alter HJ, et al.: Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996, 174:690-695.
16. Dienstag JL, Isselbacher KJ: Chronic hepatitis. In Harrison's Principles of Internal Medicine. Edited by Fauci AS, Braunwald E, Isselbacher KJ, et al. New York: McGraw Hill 1998: 1696-1704.
17. SAS Institute, Inc.: SAS Procedures Guide, Version 6. Cary, North Carolina, USA, SAS Institute Inc.; 1990.
18. SAS Institute, Inc.: SAS Technical Report P-200, SAS/SIAI Software: CALIS and LOGISTIC Procedures, Release 6.04. Cary, North Carolina, USA: SAS Institute Inc.: 1990:176-230.
19. Chen IW, Vastag KJ, Lin JH: High-performance Liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatogr 1995, 672:111-117.
20. Kopp JB, Miller KD, Falloon J: Indinavir and interstitial nephritis [letter]. Ann Intern Med 1998, 128:320-321.
21. Iroisi CL, Hollinger B, Hoots WK, et al.: A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993, 81:412-418.
22. Rumi MG, Colombo M, Gringeri A, Mannuci PM: High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990, 112:379-380.
23. Brettler DB, Alter HJ, Dienstag JI, Forsberg AD, Levine PH: Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990, 6:254-256.
24. Blanchette V, Walker I, Gill P, et al.: Hepatitis C infection in patients with hemophilia: Results of a national survey. Transfus Med Rev 1994, 8:210-217.
25. Brau N, Leaf HL, Wieczorek RL, Margolis DM: Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997, 349:924-925.
26. Racoosin JA, Kessler C.: A series of bleeding episodes in HIV-positive hemophiliacs (HEM) taking protease inhibitors. Blood 1997, 90 (suppl 1):34a.
27. Hemophilia Information Exchange: HIV Protease inhibitors and patients with hemophilia. [Medical Bulletin 250, Chapter Advisory 252]: The National Hemophilia Foundation, New York, NY, USA, 1996.
28. Merry C, McMahon C, Ryan M, et al.: Successful use of protease inhibitors in HIV-infected haemophilia patients. Br J Haematol 1998; 101:475-479.
29. Yee TT, Amrola PJ, Lee CA, Giagrande PL: Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1998, 3:219-221.
30. Teshima KT, Horowitz JD, Rosen S: Indinavir nephropathy. N Engl J Med 1997, 336:138-140.
31. Bruce RG, Munch LC, Hoven AD, et al.: Urolithiasis associated with the protease inhibitor indinavir. Urology 1997, 50:513-518.